Related Experiment Video
Updated: Jun 13, 2026

A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations
Jonathan Wadsley1, Alan Christie2, Roopinder Gillmore3
1Weston Park Cancer Centre, Whitham Rd, Sheffield, UK.
Abstract:
The management of advanced cholangiocarcinoma (CCA) is challenging. In patients with advanced CCA, gemcitabine/cisplatin combination is the standard frontline chemotherapy, with 5-fluorouracil-based regimens preserved for subsequent lines; however, the expected survival is poor. Pemigatinib was approved for locally advanced or metastatic CCA with FGFR2 fusions or rearrangement. Pemigatinib has a manageable safety profile and achieves a durable response. Nearly 50 patients with CCA have been treated with pemigatinib in the United Kingdom. However, clinical experience with pemigatinib is lacking. We present our experience with three clinical cases to illustrate the position of pemigatinib in the management of CCA and related toxicities.

